Savara Inc (NASDAQ:SVRA) Shares Bought by ProShare Advisors LLC

ProShare Advisors LLC grew its position in Savara Inc (NASDAQ:SVRA) by 28.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 40,627 shares of the company’s stock after buying an additional 9,096 shares during the quarter. ProShare Advisors LLC’s holdings in Savara were worth $125,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Savara by 26.0% in the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 48,482 shares of the company’s stock valued at $149,000 after acquiring an additional 10,000 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of Savara by 71.8% in the fourth quarter. Millennium Management LLC now owns 482,263 shares of the company’s stock valued at $1,481,000 after purchasing an additional 201,599 shares in the last quarter. Farallon Capital Management LLC grew its position in shares of Savara by 49.9% in the fourth quarter. Farallon Capital Management LLC now owns 6,835,000 shares of the company’s stock valued at $20,983,000 after purchasing an additional 2,275,000 shares during the last quarter. D. E. Shaw & Co. Inc. grew its position in shares of Savara by 314.7% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 70,560 shares of the company’s stock valued at $217,000 after purchasing an additional 53,547 shares during the last quarter. Finally, Deutsche Bank AG increased its stake in shares of Savara by 6.1% during the 4th quarter. Deutsche Bank AG now owns 927,595 shares of the company’s stock worth $2,848,000 after purchasing an additional 53,054 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Wall Street Analysts Forecast Growth

SVRA has been the topic of a number of recent research reports. Wells Fargo & Company reduced their target price on Savara from $8.00 to $7.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 28th. HC Wainwright downgraded Savara from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $6.00 to $2.00 in a research report on Thursday, May 29th. Guggenheim restated a “buy” rating and issued a $8.00 price objective (down from $9.00) on shares of Savara in a research report on Wednesday, May 28th. Finally, Evercore ISI decreased their price objective on Savara from $3.00 to $2.00 and set an “in-line” rating on the stock in a research note on Wednesday, May 28th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $7.17.

Savara Stock Up 5.3%

Shares of NASDAQ SVRA opened at $2.40 on Tuesday. The firm has a market cap of $414.81 million, a P/E ratio of -5.58 and a beta of 0.44. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. Savara Inc has a 1 year low of $1.89 and a 1 year high of $5.11. The firm’s 50 day moving average price is $2.91 and its 200 day moving average price is $2.94.

Savara (NASDAQ:SVRA) last posted its quarterly earnings data on Tuesday, May 13th. The company reported ($0.12) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.12). As a group, sell-side analysts anticipate that Savara Inc will post -0.45 earnings per share for the current year.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.